Altshuler Shaham Ltd Has $1.42 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Altshuler Shaham Ltd boosted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 73.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,641 shares of the medical research company’s stock after acquiring an additional 7,886 shares during the quarter. Altshuler Shaham Ltd’s holdings in Edwards Lifesciences were worth $1,421,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of EW. Nordea Investment Management AB lifted its stake in shares of Edwards Lifesciences by 1,224.1% in the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock valued at $123,261,000 after purchasing an additional 1,488,791 shares during the last quarter. Telos Capital Management Inc. boosted its stake in shares of Edwards Lifesciences by 158.2% during the 4th quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock worth $6,970,000 after acquiring an additional 56,000 shares in the last quarter. Arlington Trust Co LLC increased its holdings in shares of Edwards Lifesciences by 5,092.4% during the 4th quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock valued at $938,000 after acquiring an additional 12,069 shares during the last quarter. Versor Investments LP lifted its holdings in Edwards Lifesciences by 83.3% in the 3rd quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock worth $311,000 after purchasing an additional 2,043 shares during the last quarter. Finally, HealthInvest Partners AB acquired a new position in Edwards Lifesciences during the fourth quarter valued at approximately $1,587,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, SVP Robert W.A. Sellers sold 12,210 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $87.00, for a total transaction of $1,062,270.00. Following the transaction, the senior vice president now directly owns 13,087 shares in the company, valued at $1,138,569. The sale was disclosed in a filing with the SEC, which is available through this link. In other Edwards Lifesciences news, SVP Robert W.A. Sellers sold 12,210 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $87.00, for a total value of $1,062,270.00. Following the sale, the senior vice president now owns 13,087 shares in the company, valued at $1,138,569. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total value of $1,212,624.00. Following the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at $14,639,824.29. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 230,693 shares of company stock valued at $20,310,942. Insiders own 1.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Oppenheimer boosted their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 18th. Wells Fargo & Company raised their target price on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a report on Friday, April 26th. Piper Sandler upped their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a report on Friday, April 26th. StockNews.com upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Finally, Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $93.27.

Edwards Lifesciences Trading Up 2.7 %

Shares of NYSE:EW traded up $2.33 during mid-day trading on Thursday, reaching $87.42. The stock had a trading volume of 3,421,899 shares, compared to its average volume of 3,709,712. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The firm has a market cap of $52.68 billion, a PE ratio of 37.68, a price-to-earnings-growth ratio of 3.59 and a beta of 1.10. The firm has a 50 day simple moving average of $90.03 and a two-hundred day simple moving average of $79.73.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. On average, research analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.